Hormones and longevity. Why balance matters more than a single result

1. Why hormones are a longevity topic, not just an endocrinology one

Hormones are the body''s signalling system — they regulate metabolism, body composition, mood, sleep, bone density and cardiovascular function. In the context of healthy longevity the question is not whether a given hormone is "high" or "low" in isolation, but whether age-related hormonal change is unfolding in a way that preserves function (healthspan) or accelerates the accumulation of risk. Longevity science increasingly shows that the endocrine system is not a single switch but a network of interconnected axes (hypothalamic–pituitary–gonadal, –thyroid and –adrenal) whose balance shifts across decades.

2. Testosterone and andropause: what large meta-analyses show

Testosterone in men declines by roughly 1–2% per year after the age of 30–40 — a physiological phenomenon often called "andropause", although the term is not a precise equivalent of menopause. From a longevity perspective the key question is not "does it decline" but "how low, and with what consequence". The largest analysis to date — an individual participant data meta-analysis of more than 24,000 men (Yeap et al., Annals of Internal Medicine, 2024) — found that all-cause mortality risk rises below a testosterone threshold of about 7.4 nmol/L (213 ng/dL), and cardiovascular mortality risk below about 5.3 nmol/L (153 ng/dL). These are observational data, so they do not automatically prove that pharmacologically raising testosterone lowers that risk — see the limitations section below. See also: testosterone.

3. Estrogens and menopause: why timing matters

In women, the menopausal transition brings a steeper decline in the main estrogen, estradiol, than men experience. The American Heart Association scientific statement (El Khoudary et al., Circulation, 2020) summarises evidence that the perimenopausal period is a time of accelerated, unfavourable changes in lipid profile, endothelial function and fat distribution — translating into higher cardiovascular risk in later decades. The same statement describes the timing hypothesis: data from trials such as ELITE and KEEPS suggest that the vascular effect of menopausal hormone therapy differs depending on whether it is started close to menopause or many years later. This is not a blanket recommendation — the decision is always individual and made with a clinician, taking the full risk profile into account. See also: estradiol and AMH.

4. Thyroid and cortisol: paradoxes that teach humility

The thyroid offers one of the more interesting paradoxes in ageing science. Intuitively one might expect lower TSH (a seemingly "more active" thyroid) to favour better health. Yet a review by van Heemst (Nature Reviews Endocrinology, 2024) shows that with age — and especially among exceptionally long-lived people, including centenarians — there is a tendency toward higher, not lower, TSH, and lower (not higher) thyroid activity is described as a familial trait associated with longevity. Simple slogans of the "higher hormone = better" type do not hold in the biology of ageing, and treating subclinical hypothyroidism in older adults without symptoms is not always beneficial. See also: TSH.

Cortisol, the main stress-response hormone, matters mostly as a diurnal rhythm rather than a single value. The Whitehall II cohort study (Kumari et al., Journal of Clinical Endocrinology & Metabolism, 2011), covering more than 4,000 people, found that a flattened daytime cortisol decline (evening values staying relatively high) was associated with increased cardiovascular mortality — independently of morning cortisol. See also: cortisol.

5. Is routine hormone testing worthwhile for longevity?

The answer depends on clinical context, age and symptoms — there is no universal "longevity hormone panel". Testing testosterone, estradiol, TSH or cortisol makes sense mainly when symptoms suggest a disorder (persistent fatigue, changes in libido, irregular menstrual cycles, cold or heat intolerance), or as part of a plan agreed with a clinician around the perimenopausal or andropausal years. A single out-of-range result rarely justifies immediate intervention — the trend over time and the wider picture (sleep, body composition, physical activity, metabolic profile) matter more. See also: DHEA-S.

Study limitations

Most of the data cited above come from observational studies and cohort meta-analyses — they show association, not necessarily causation. Reverse causality is plausible: chronic disease and declining health can lower testosterone or disturb cortisol rhythm rather than the other way round. Evidence that pharmacologically raising a hormone improves hard endpoints (survival, cardiovascular events) is considerably weaker than the evidence for the association itself. A large individual patient data meta-analysis of testosterone therapy RCTs (Hudson et al., The Lancet Healthy Longevity, 2022) found no increase in cardiovascular risk over short- and medium-term follow-up, but also did not clearly confirm reduced mortality — and long-term safety data remain limited. Similarly for menopausal hormone therapy: the effect depends strongly on timing, route of administration and preparation, which makes generalisation difficult. The mechanism behind the TSH paradox in long-lived people is not fully understood.

One small step

If you notice symptoms that could point to a hormonal disorder (chronic fatigue, disturbed sleep, changes in libido, irregular cycles), write them down and discuss them with a clinician before ordering a broad hormone panel — symptom context helps select the right tests instead of "checking everything" at random.

Related: Heart health and longevity.